India’s obesity treatment market is expected to change quickly by year-end as oral GLP1 weight-loss pills become widely available, including new options from China. These tablet therapies promise a cheaper, easier alternative to injectable GLP1 drugs, which could boost patient adoption as convenience and affordability rise. Market analysts expect demand to accelerate as more people can access treatment.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
